NCT00996502 - Study of Bevacizumab and Erlotinib for Patients With Hormone Refractory Prostate Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

July 31, 2006

Primary Completion Date

March 31, 2010

Study Completion Date

March 31, 2010

Conditions

Prostate Cancer

Interventions

DRUG

Docetaxel

"Phase I:~* Cohort 1: 55mg/m2 of Docetaxel on Day 1 of the cycle~* Cohort 2: 65mg/m2 of Docetaxel on Day 1 of the cycle~* Cohort 3: 75mg/m2 of Docetaxel on Day 1 of the cycle"

DRUG

Bevacizumab

15mg/kg of Bevacizumab every 3 weeks

DRUG

Erlotinib

200 mg of Erlotinib PO daily days 2-16

DRUG

Prednisone

5 mg of Prednisone PO bid

Trial Locations (1)

10032

Columbia University Medical Center, New York